

Market Round-up

V11 – 3rd August, 2018

General Market News:

- The **EMA** has approved **Norvartis' Aimovig (erenumab)**, making it Europe's first treatment specifically designed to prevent **migraine**.
http://www.pharmatimes.com/news/novartis_migraine_drug_gets_ema_approval_1246290
- **MSD** announced that their **Keytruda**-chemo combo had received a recommendation from the **European Medicines Agency**
<https://www.fiercepharma.com/pharma/positive-ema-news-for-merck-s-keytruda-rubs-salt-bristol-myers-wounds>
- **LEO Pharma** to expand its lead in medical dermatology with acquisition of **Bayer's** prescription dermatology unit
<https://www.businesswire.com/news/home/20180731005552/en/LEO-Pharma-Expand-Lead-Medical-Dermatology-Acquisition>
- **Pfizer** beats profit estimates but lowers 2018 revenue forecast
<https://www.channelnewsasia.com/news/business/pfizer-beats-profit-estimates-but-lowers-2018-revenue-forecast-10577720>
- **Shire** profit edges higher ahead of **Takeda** sale
<https://www.reuters.com/article/us-shire-results/shire-profit-edges-higher-ahead-of-takeda-sale-idUSKBN1KL1J7>
- **Beats Medical** expands with launch of app for children with **dyspraxia**
<https://www.independent.ie/business/technology/beats-medical-expands-with-launch-of-app-for-children-with-dyspraxia-37141334.html>
If you're unfamiliar with Beats Medical, take a few minutes to watch CEO Dr Ciara Clancy's inspirational talk at our Annual Business Day on April 2018 at this link: [VIEW VIDEO](#)
- **HSE** prescriptions for **antidepressants** and **anxiety medications** up by two thirds since 2009
<http://jrnl.ie/4157452>
- **Pfizer** has reported it is dropping drugs from its **Type 1 diabetes** and **cancer** early-phase pipeline.
<https://www.biospace.com/article/amid-q2-report-pfizer-drops-diabetes-and-cancer-drugs/>

Biosimilars/Biologics:

- **Pfizer** announces EU approval of Biosimilar **Trazimera**
<https://www.streetinsider.com/Corporate+News/Pfizer+%28PFE%29+Announces+EU+Approval+of+Biosimilar+TRAZIMERA/14450408.html>
- **Novartis' Sandoz** gets European Commission approval For Biosimilar **Hyrimoz**
<https://www.nasdaq.com/article/novartis-sandoz-gets-european-commission-approval-for-biosimilar-hyrimoz-20180727-00528>

Drug Approvals:

- **MSD** announced that their **Keytruda**-chemo combo has received a recommendation from the **EMA**.
<https://www.fiercepharma.com/pharma/positive-ema-news-for-merck-s-keytruda-rubs-salt-bristol-myers-wounds>
- The **EMA** has approved **Norvartis' Aimovig (erenumab)**, making it Europe's first treatment specifically designed to prevent **migraine**.
http://www.pharmatimes.com/news/novartis_migraine_drug_gets_ema_approval_1246290
- **Pfizer's Xeljanz** cleared for **ulcerative colitis** in Europe
http://www.pharmatimes.com/news/pfizers_xeljanz_cleared_for_ulcerative_colitis_in_europe_1246474?utm_source=dlvr.it&utm_medium=twitter
- **Aegerion Pharmaceuticals' Myalepta** - a treatment for the ultra-rare condition lipodystrophy - has been approved by the EMA to treat the complications of **leptin deficiency** in **lipodystrophy** patients.
http://www.pharmatimes.com/news/first_treatment_for_lipodystrophy_approved_in_europe_1246475?utm_source=dlvr.it&utm_medium=twitter

Further Reading:

The **European Network of Centres for Pharmacoepidemiology & Pharmacovigilance** (ENCePP) has updated its *Guide on Methodological Standards in Pharmacoepidemiology* with new guidance on studying the use and effects of medicines in real-life studies
http://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml